Delårsrapport 2

Delårsrapport för Q2 2016 publiceras

Contact us

Kristian Lykke Fick

Send e-mail

Twitter Linkedin Facebook Youtube

As part of Coegin Pharma AB’s hub & spoke “portfolio” business model, with clear benefits to investors, Coegin Pharma AB has established the Swedish portfolio company Follicum AB to further develop a highly promising novel and proprietary dermatological drug candidate FOL005. Follicum AB will primarily be managed and financed separately from Coegin Pharma AB.